» Articles » PMID: 20407318

Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas

Overview
Date 2010 Apr 22
PMID 20407318
Citations 135
Authors
Affiliations
Soon will be listed here.
Abstract

Although there are recognized differences in the type of ovarian carcinomas between those tumors diagnosed at low versus high stage, there is a lack of data on stage distribution of ovarian carcinomas diagnosed according to the current histopathologic criteria from large population-based cohorts. We reviewed full slide sets of 1009 cases of 2555 patients diagnosed with ovarian carcinoma that were referred to the British Columbia Cancer Agency over a 16-year period (1984 to 2000). On the basis of the reviewed cases we extrapolated the distribution of tumor type in low-stage (I/II) and high-stage (III/IV) tumors. We then compared the frequencies with those seen in a large hospital practice. The overall frequency of tumor types was as follows: high-grade serous-68.1%, clear-cell-12.2%, endometrioid-11.3%, mucinous-3.4%, low-grade serous-3.4%, rare types-1.6%. High-grade serous carcinomas accounted for 35.5% of stage I/II tumors and 87.7% of stage III/IV tumors. In contrast, clear-cell (26.2% vs. 4.5%), endometrioid (26.6% vs. 2.5%), and mucinous (7.5% vs. 1.2%) carcinomas were relatively more common among the low-stage versus high-stage tumors. This distribution was found to be very similar in 410 consecutive cases from the Washington Hospital Center. The distribution of ovarian carcinoma types differs significantly in patients with low-stage versus high-stage ovarian carcinoma when contemporary diagnostic criteria are used, with consistent results seen in 2 independent case series. These findings reflect important biological differences in the behavior of the major tumor types, with important clinical implications.

Citing Articles

Infiltration of CD8 cytotoxic T-cells and expression of PD-1 and PD-L1 in ovarian clear cell carcinoma.

Fu M, Zhou H, Yang J, Cao D, Yuan Z Sci Rep. 2025; 15(1):4716.

PMID: 39922892 PMC: 11807128. DOI: 10.1038/s41598-025-89270-z.


Ovarian clear cell carcinoma: open questions on the management and treatment algorithm.

Rosso R, Turinetto M, Borella F, Chopin N, Meeus P, Laine A Oncologist. 2025; 30(1).

PMID: 39846983 PMC: 11756325. DOI: 10.1093/oncolo/oyae325.


Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed....

Mukherjee U, Hockings H, Counsell N, Patel A, Narayanan P, Wilkinson K BMJ Open. 2025; 14(12):e091262.

PMID: 39806715 PMC: 11667365. DOI: 10.1136/bmjopen-2024-091262.


Leveraging Multi-omics to Disentangle the Complexity of Ovarian Cancer.

Lin S, Nguyen L, McMellen A, Leibowitz M, Davidson N, Spinosa D Mol Diagn Ther. 2024; 29(2):145-151.

PMID: 39557776 DOI: 10.1007/s40291-024-00757-3.


The surgical, histopathological characteristics, and survival outcome of ovarian clear cell carcinoma: a retrospective case series sharing the experience of a tertiary cancer centre.

El Tawab S, Nistor S, Roux R, Manek S, Gaitskell K, Ahmed A Transl Cancer Res. 2024; 13(9):5037-5049.

PMID: 39430857 PMC: 11483364. DOI: 10.21037/tcr-24-83.